Patents Examined by Michel Graffeo
-
Patent number: 7276514Abstract: The invention includes composition comprising substantially purified pyrroloquinoline quinone, that are useful in methods for the treatment and prevention of cardiac injury caused by hypoxia or ischemia. The invention also includes methods for the treatment and prevention of cardiac injury comprising contacting a compression of the invention with a human patient.Type: GrantFiled: May 15, 2002Date of Patent: October 2, 2007Assignee: Charitable Leadership Foundation - Medical Technology Acceleration ProgramInventor: Paul J. Davis
-
Patent number: 7273872Abstract: Methods for inhibiting an inflammatory cytokine cascade in a patient are provided. The methods are directed to treating the patient with a cholinergic agonist in an amount sufficient to inhibit the inflammatory cytokine cascade, wherein the cholinergic agonist is selective for an ?7 nicotinic receptor.Type: GrantFiled: December 5, 2003Date of Patent: September 25, 2007Assignee: The Feinstein Institute for Medical ResearchInventors: Kevin J. Tracey, Hong Wang
-
Patent number: 7238715Abstract: A method of treating a patient suffering from pancreatitis comprising treating said patient with a therapeutically effective amount of a cholinergic agonist selective for an ?7 nicotinic receptor in an amount sufficient to decrease the amount of the proinflammatory cytokine that is released from a macrophage wherein said condition is acute pancreatitis. The compounds of the present invention include a quaternary analog of cocaine; (1-aza-bicyclo[2.2.2]oct-3-yl)-carbamic acid 1-(2-fluorophenyl)-ethyl ester; a compound of formula (I), a compound of formula (II), a compound of formula (III), a compound of formula (IV), and an oligonucleotide or mimetic capable of attenuating the symptoms of acute pancreatitis wherein the oligonucleotide or mimetic consists essentially of a sequence greater than 5 nucleotides long that is complementary to an mRNA of an ?7 cholinergic receptor.Type: GrantFiled: September 30, 2004Date of Patent: July 3, 2007Assignee: The Feinstein Institute for Medical ResearchInventors: Kevin J. Tracey, Hong Wang
-
Patent number: 7211587Abstract: An object of the present invention is to provide compounds having potent antitumor activity. The compounds according to the present invention are compounds represented by formula (I) or pharmaceutically acceptable salts or solvates thereof: wherein X and Z represent CH or N; Y represents O or S; R1, R2, and R3 represent H, alkoxy or the like; R4 represents H; R5, R6, R7, and R8 represent H, halogen, alkoxy or the like; R9 and R10 represent H, alkyl or the like; and R11 represents optionally substituted azolyl.Type: GrantFiled: June 7, 2004Date of Patent: May 1, 2007Assignee: Kirin Beer Kabushiki KaishaInventors: Kazuo Kubo, Teruyuki Sakai, Rika Nagao, Yasunari Fujiwara, Toshiyuki Isoe, Kazumasa Hasegawa
-
Patent number: 7199126Abstract: The present invention provides compositions of matter, kits and methods for their use in the treatment of MAP kinase-related conditions and/or HMG-CoA reductase-related conditions. In particular, the invention provides compositions for treating inflammatory and/or cardiovascular conditions in an animal subject by inhibiting p38? MAP kinase and/or HMG-CoA reductase, as well as providing formulations and modes of administering such compositions. The invention further provides methods for the rational design of inhibitors of MAP kinase, HMG-CoA reductase, or both for use in the practice of the present invention.Type: GrantFiled: April 29, 2005Date of Patent: April 3, 2007Assignee: Pharmix CorporationInventors: John Griffin, Guido Lanza, Jessen Yu
-
Patent number: 7183285Abstract: The present invention provides compositions of matter, kits and methods for their use in the treatment of MAP kinase-related conditions and/or HMG-CoA reductase-related conditions. In particular, the invention provides compositions for treating inflammatory and/or cardiovascular conditions in an animal subject by inhibiting p38? MAP kinase and/or HMG-CoA reductase, as well as providing formulations and modes of administering such compositions. The invention further provides methods for the rational design of inhibitors of MAP kinase, HMG-CoA reductase, or both for use in the practice of the present invention.Type: GrantFiled: April 29, 2005Date of Patent: February 27, 2007Assignee: Pharmix Corp.Inventors: John Griffin, Guido Lanza, Jessen Yu
-
Patent number: 7163945Abstract: The present invention provides compositions of matter, kits and methods for their use in the treatment of MAP kinase-related conditions and/or HMG-CoA reductase-related conditions. In particular, the invention provides compositions for treating inflammatory and/or cardiovascular conditions in an animal subject by inhibiting p38? MAP kinase and/or HMG-CoA reductase, as well as providing formulations and modes of administering such compositions. The invention further provides methods for the rational design of inhibitors of MAP kinase, HMG-CoA reductase, or both for use in the practice of the present invention.Type: GrantFiled: April 29, 2005Date of Patent: January 16, 2007Assignee: Pharmix Corp.Inventors: John Griffin, Guido Lanza, Jessen Yu
-
Patent number: 7157459Abstract: The present invention provides an improved method for treating lung cancer, preferably non-small cell lung cancer, by orally administering UFT to postoperative lung cancer patients.Type: GrantFiled: April 27, 2005Date of Patent: January 2, 2007Assignee: Taiho Pharmaceutical Co., Ltd.Inventors: Mitsuo Ohta, Hiromi Wada, Harubumi Kato, Yukito Ichinose, Masahiro Tsuboi
-
Patent number: 7125873Abstract: The present invention is directed to compounds which are inhibitors of the dipeptidyl peptidase-IV enzyme (“DP-IV inhibitors”) and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.Type: GrantFiled: July 5, 2002Date of Patent: October 24, 2006Assignee: Merck & Co., Inc.Inventors: Scott D Edmondson, Michael H. Fisher, Dooseop Kim, Malcolm Maccoss, Emma R. Parmee, Ann E Weber, Jinyou Xu
-
Patent number: 7064132Abstract: A compound, process and method for increasing external auditory canal patency while simultaneously preventing the occurrence of otitis externa is disclosed wherein an aerosolized mixture of lipid crystals comprised of a mixture of one or more lipids surfactants and one or more spreading agents selected from the group consisting of sterols, lipids, fatty acids, cholesteryl esters, phospholipids, carbohydrates, nucleic acids and proteins, in powder form, and one or more fluorocarbon propellants is administered directly to the external auditory canal. Upon administration, the propellant(s) are evaporated from the mixture and the lipid crystals are deposited upon an air/liquid interface resident upon epithelial tissue lining the external auditory canal.Type: GrantFiled: December 11, 2001Date of Patent: June 20, 2006Assignee: Scientific Development and Research, Inc.Inventor: Alan J. Mautone
-
Patent number: 7048912Abstract: A polymer for use in an oral care composition which includes a monomer repeat unit containing an active material covalently bonded to a hydrolyzable side group of said monomer unit, and a spacer group positioned between the main chain of said polymer and said hydrolyzable side group, said polymer having a predetermined rapid rate of aqueous hydrolysis to release said active material therefrom.Type: GrantFiled: June 13, 2003Date of Patent: May 23, 2006Assignee: ISP Investments Inc.Inventor: Krystyna Plochocka